On September 1, 2024, the "China Heart Congress Innovation and Translation Forum and Jingxi Innovative Pharma-Device Industry Development Conference" was grandly held in Beijing. Attendees included Xu Xinchao, Deputy Secretary-General of the Beijing Municipal Government; Hu Shengshou, Academician of the Chinese Academy of Engineering, Director of the National Center for Cardiovascular Diseases, and President of Fuwai Hospital; Yu Huafeng, Secretary of the Mentougou District Committee; Lü Chenfei, Deputy Secretary of the Mentougou District Committee and District Mayor, along with numerous government leaders, experts, scholars, and corporate representatives. The event featured in-depth discussions on the collaborative development of medical education, research, and prevention in the cardiovascular field, as well as innovations in pharmaceuticals and medical devices. During the conference, Baheal Pharma and Fuwai Hospital—under the Chinese Academy of Medical Sciences—held a signing ceremony to establish the "Fuwai Hospital-Baheal Pharma Myocardial Repair and Regeneration Drug Joint R&D Center," aiming to explore new models for cardiovascular disease prevention and treatment and advance the translation of high-quality research to benefit patients.

Signing Ceremony for the Fuwai Hospital-BAHEAL

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, presenting a significant public health challenge in China. According to the "China Cardiovascular Health and Disease Report 2023," the number of CVD patients in China has reached 330 million, with approximately 8.9 million suffering from heart failure and around 4.3 million deaths annually attributed to cardiovascular diseases. This situation is exacerbated by an aging population, resulting in increasing prevalence and mortality rates. In light of these pressing concerns, exploring new avenues for myocardial repair and regeneration, and accelerating the translation of research findings into clinical practice, has become essential for improving cardiovascular disease prevention and treatment.

As a leading domestic and internationally renowned center for innovative cardiovascular care, prevention, research translation, and talent cultivation, Fuwai Hospital is devoted to cutting-edge research in the field of cardiovascular diseases. The hospital boasts extensive clinical resources and innovative research achievements. The establishment of a joint R&D center between Baheal Group and Fuwai Hospital aims to enhance cardiovascular disease prevention and treatment in China. Leveraging Fuwai Hospital's clinical resources and research strengths, along with Baheal's expertise in pharmaceutical innovation and commercialization, the partnership will focus on advancing the development and translation of myocardial repair and regeneration therapies. This collaboration seeks to efficiently integrate basic research with clinical applications, ultimately providing safer and more effective treatment options for cardiovascular disease patients.

As a veteran "industry investor" in the pharmaceutical and healthcare sector, BAHEAL has long committed to optimizing medical scenarios through technological innovation. Focusing on three key areas—innovative drugs, high-end medical devices, and fundamental research platforms—BAHEAL invests in and incubates groundbreaking research outcomes. By partnering with national research institutions, BAHEAL seeks to uncover First-in-Class potential and breakthrough technologies to overcome critical challenges. With a comprehensive innovation incubation system and eco-mechanism, BAHEAL strategically allocates resources across innovation development, clinical research, manufacturing, and commercialization, effectively acting as a "catalyst" for pharmaceutical innovation. This approach accelerates the translation of research findings into clinical applications. Recognizing the significant threat cardiovascular diseases pose to human health, BAHEAL has strategically invested in this field for years, fostering a synergistic innovation ecosystem across multiple avenues.

In the realm of fundamental research, BAHEAL has previously collaborated with the National Center for Cardiovascular Diseases and Fuwai Hospital to incubate the innovative company Baheal Wisdom Heart. This partnership leverages primary human cardiomyocyte resources and related patented technologies to drive cutting-edge research and facilitate the translation of scientific findings into drug screening, in vitro diagnostic reagents for cardiovascular diseases, and innovative drugs. In the high-end medical devices sector, BAHEAL has successfully incubated the fully magnetically levitated artificial heart with independent intellectual property rights in China—CH® VAD, which has been commercialized and is benefiting numerous patients with end-stage heart failure. The establishment of the joint R&D center will allow BAHEAL to further extend its footprint in the cardiovascular field, particularly in innovative drugs and in vitro diagnostics (IVD), exploring and expanding safer, more precise, and more efficient innovative diagnostic and treatment solutions.

Currently, China's pharmaceutical industry is at a critical juncture for breakthroughs in original innovation. Guided by top-level designs that adhere to the laws of life sciences development, BAHEAL is accelerating its efforts to drive the emergence of new productive forces within the pharma-health industry through technological innovation. This aims to foster the creation of a cluster of original innovation in China's pharmaceutical sector. Looking forward, BAHEAL will continue to focus on patient needs, promoting the translation of more clinically valuable innovations into practical applications, ultimately benefiting patients.